Fax: (773) 702-8519
Clinical significance of KISS1 protein expression for brain invasion and metastasis†
Version of Record online: 16 SEP 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 8, pages 2096–2105, 15 April 2012
How to Cite
Ulasov, I. V., Kaverina, N. V., Pytel, P., Thaci, B., Liu, F., Hurst, D. R., Welch, D. R., Sattar, H. A., Olopade, O. I., Baryshnikov, A. Y., Kadagidze, Z. G. and Lesniak, M. S. (2012), Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer, 118: 2096–2105. doi: 10.1002/cncr.26525
We thank Lori Loftis, Deidre Anderson, Zakiya Moton, and Tatyana Grushko (Department of Surgery, Pathology and Medicine, University of Chicago) for their precious help in obtaining clinicopathological data and technical assistance with the IRB application. The authors also extend thanks to Leslie Martin and LeiAnn Arceneaux (Pathology Core, University of Chicago) for their help with the tissue microarray database and experimental design. Finally, we are very grateful to the Drs. Theodore Karrison and Dingcai Cao (Department of Health Studies and Surgery, University of Chicago) for the help with statistical analysis.
- Issue online: 6 APR 2012
- Version of Record online: 16 SEP 2011
- Manuscript Accepted: 4 AUG 2011
- Manuscript Revised: 7 JUL 2011
- Manuscript Received: 25 APR 2011
- breast cancer;
- brain metastases;
Metastases to the brain represent a feared complication and contribute to the morbidity and mortality of breast cancer. Despite improvements in therapy, prognostic factors for development of metastases are lacking. KISS1 is a metastasis suppressor that demonstrates inhibition of metastases formation in several types of cancer. The purpose of this study was to determine the importance of KISS1 expression in breast cancer progression and the development of intracerebral lesions.
In this study, we performed a comparative analysis of 47 brain metastases and 165 primary breast cancer specimens by using the antihuman KISS1 antibody. To compare KISS1 expression between different groups, we used a 3-tier score and the automated score computer software (ACIS) evaluation. To reveal association between mRNA and protein expression, we used quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. Significance of immunohistochemistry stainings was correlated with clinicopathological data.
We identified that KISS1 expression is significantly higher in primary breast cancer compared with brain metastases (P < .05). The mRNA analysis performed on 33 selected ductal carcinoma brain metastatic lesions and 36 primary ductal carcinomas revealed a statistically significant down-regulation of KISS1 protein in metastatic cases (P = .04). Finally, we observed a significant correlation between expression of KISS1 and metastasis-free survival (P = .04) along with progression of breast cancer and expression of KISS1 in primary breast cancer specimens (P = .044).
In conclusion, our study shows that breast cancer expresses KISS1. Cytoplasmic expression of KISS1 may be used as a prognostic marker for increased risk of breast cancer progression. Cancer 2012;. © 2011 American Cancer Society.